TELIX Pharmaceuticals Ltd Market Cap ($3.11 Billion)

$3.11 Billion USD · AU$4.39 Billion AUD · Rank #4633

Market Cap & Net Worth: TELIX Pharmaceuticals Ltd (TLX)

TELIX Pharmaceuticals Ltd market cap. TELIX Pharmaceuticals Ltd (AU:TLX) has a market capitalization of $3.11 Billion (AU$4.39 Billion) as of November 1, 2026. Listed on the AU stock exchange, this Australia-based company holds position #4633 globally and #118 in its home market, demonstrating a -3.88% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying TELIX Pharmaceuticals Ltd's stock price AU$13.13 by its total outstanding shares 334724485 (334.72 Million). Also see TLX cash flow conversion for how efficiently the company converts equity into cash flow.

TELIX Pharmaceuticals Ltd Market Cap History (2017–2026)

TELIX Pharmaceuticals Ltd market cap history from 2017 to 2026. Data shows growth from $146.84 Million to $3.11 Billion (37.23% CAGR). Check TLX stock price for real-time trading data and today's change.

Index Memberships

TELIX Pharmaceuticals Ltd is a constituent of 6 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
Australia All Ordinaries AORD	$2.01 Trillion	0.15%	#101 of 495
S&P/ASX All Australian 200 AXAT	$1.92 Trillion	0.16%	#98 of 200
S&P/ASX 200 AXJO	$1.89 Trillion	0.16%	#94 of 200
S&P/ASX 200 Accumulated AXJOA	$1.89 Trillion	0.16%	#94 of 200
S&P/ASX 300 AXKO	$2.16 Trillion	0.14%	#106 of 300
ASX Small Ordinaries AXSO	$284.01 Billion	1.09%	#26 of 200

Weight: TELIX Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

TELIX Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how TELIX Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore TLX net assets growth trend to track how rapidly the company is growing its equity base year over year.

Latest Price to Sales (P/S) Ratio

7.44x

TELIX Pharmaceuticals Ltd's market cap is 7.44 times its annual revenue

Industry average: 3868.91x Lower than industry average

Latest Price to Earnings (P/E) Ratio

116.76x

TELIX Pharmaceuticals Ltd's market cap is 116.76 times its annual earnings

Industry average: 1.51x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2017	$146.84 Million	$403.47K	-$6.38 Million	363.95x	N/A
2018	$153.95 Million	$195.14K	-$13.83 Million	788.89x	N/A
2019	$367.10 Million	$3.48 Million	-$27.87 Million	105.34x	N/A
2020	$895.25 Million	$5.21 Million	-$44.89 Million	171.73x	N/A
2021	$1.84 Billion	$7.60 Million	-$80.51 Million	241.64x	N/A
2022	$1.72 Billion	$160.10 Million	-$104.08 Million	10.75x	N/A
2023	$2.39 Billion	$502.55 Million	$5.21 Million	4.75x	458.13x
2024	$5.83 Billion	$783.21 Million	$49.92 Million	7.44x	116.76x

Competitor Companies of TLX by Market Capitalization

Companies near TELIX Pharmaceuticals Ltd in the global market cap rankings as of November 1, 2026. Also see TELIX Pharmaceuticals Ltd balance sheet assets for a full breakdown of the balance sheet.

Key companies related to TELIX Pharmaceuticals Ltd by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#182	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$130.90 Billion	$558.88
#371	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$76.14 Billion	$927.89
#412	CSL Ltd	AU:CSL	$68.91 Billion	AU$200.73
#495	Moderna Inc	NASDAQ:MRNA	$54.14 Billion	$221.72

Market Capitalization of TELIX Pharmaceuticals Ltd (2017–2026)

Market capitalization of TELIX Pharmaceuticals Ltd from 2017 to today. Between 2017 and today, TELIX Pharmaceuticals Ltd's market cap moved from $146.84 Million to $ 3.11 Billion, with a yearly change of 37.23%.

Year	Market Cap	Change (%)
2026	AU$3.11 Billion	+17.23%
2025	AU$2.65 Billion	-54.49%
2024	AU$5.83 Billion	+144.15%
2023	AU$2.39 Billion	+38.65%
2022	AU$1.72 Billion	-6.19%
2021	AU$1.84 Billion	+105.03%
2020	AU$895.25 Million	+143.87%
2019	AU$367.10 Million	+138.46%
2018	AU$153.95 Million	+4.84%
2017	AU$146.84 Million	--

End of Day Market Cap According to Different Sources

On Oct 31st, 2026 the market cap of TELIX Pharmaceuticals Ltd was reported to be:

Source	Market Cap
Yahoo Finance	$3.11 Billion USD
MoneyControl	$3.11 Billion USD
MarketWatch	$3.11 Billion USD
marketcap.company	$3.11 Billion USD
Reuters	$3.11 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.11 Billion

AU$4.39 Billion AUD

Market Cap Rank

#4633 Global

#118 in Australia

Share Price

AU$13.13

Change (1 day)

-2.60%

52-Week Range

AU$8.63 - AU$17.85

All Time High

AU$31.14